Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinct effects of V617F and exon12-mutated JAK2 expressions on erythropoiesis in a human induced pluripotent stem cell (iPSC)-based model.

Scientific reports - 4 Mar 2021

Nilsri Nungruthai, Jangprasert Panchalee, Pawinwongchai Jaturawat, Israsena Nipan, Rojnuckarin Ponlapat

Abstract excerpt

Activating mutations affecting the JAK-STAT signal transduction is the genetic driver of myeloproliferative neoplasms (MPNs) which comprise polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis. The JAK2p.V617F mutation can produce both erythrocytosis in PV and thrombocytosis in ET, while JAK2 exon 12 mutations cause only erythrocytosis. We hypothesized that these two mutations activated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erythropoiesis
Share to Polycythemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to STAT Transcription Factors

Share to STAT1 Transcription Factor

Share to Thrombocythemia, Essential

Share to Thrombocytosis

Source

Open in PubMed Open full text

Identifiers

PMID: 33664283
DOI: 10.1038/s41598-021-83895-6
PMCID: PMC7933160

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct effects of V617F and exon12-mutated JAK2 expressions on erythropoiesis in a human induced pluripotent stem cell (iPSC)-based model.PMID 33664283Read ↗

Mutated JAK2 signal transduction in human induced pluripotent stem cell (iPSC)-derived megakaryocytes.Semantic proximity Read ↗

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.Semantic proximity Read ↗

Differential Sensitivity to JAK Inhibitory Drugs by Isogenic Human Erythroblasts and Hematopoietic Progenitors Generated from Patient-Specific Induced Pluripotent Stem CellsSemantic proximity Read ↗

Establishment of isogenic induced pluripotent stem cells with or without pathogenic mutation for understanding the pathogenesis of myeloproliferative neoplasms.Semantic proximity Read ↗

Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche.Semantic proximity Read ↗

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Semantic proximity Read ↗

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative DisordersSemantic proximity Read ↗

Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.Semantic proximity Read ↗

Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.Semantic proximity Read ↗

Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Genome editing to model and reverse a prevalent mutation associated with myeloproliferative neoplasmsSemantic proximity Read ↗

The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspectiveSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.